therapy

Bart Barlogie Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 BART BARLOGIE, University of Arkansas, Little Rock A treatment known as “total therapy

Kenneth Anderson Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston Multiple myeloma may soon be consi

Robert Mayer ROBERT MAYER, Dana-Farber Cancer Institute, Boston One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some

Jose Baselga JOSE BASELGA, Vall d’Hebron Hospital, Barcelona RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The in

Richard Stone RICHARD STONE, Dana-Farber Cancer Institute, Boston GEORGE CANELLOS, Dana-Farber Cancer Institute New data shows that dasatinib is giving durable responses in patients with chronic phase

Zakari Aliyu REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta ZAKARI ALIYU, Howard University, Washington DC Nigeria has the highest incidence of sickle cell anemi

George Sopko

Gregg Stone REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GREGG STONE, Columbia University, New York New light has been thrown on the u

Uwe Zeymer REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida UWE ZEYMER, Herzzentrum Ludwigshafen, Germany The gl

Anthony Fung REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida ANTHONY FUNG, University of British Columbia, Vanc

REFERENCE: Abstract: Late Breaking Clinical Trials, Session 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida LESLEE SHAW, Emory University, Atlanta COMMENT: DANI

Jose Baselga Gordon McVie REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona CO

Diana Lockwood REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 DIANA LOCKWOOD, London School of Hygiene and Tropical Medicine ICAAC delega

Pierre Laurent-Puig Bill Hait REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris COMMEN

Simon Lewin REFERENCE: PLoS Med 4(7):e238. doi:10.1371/journal.pmed.0040238 SIMON LEWIN, London School of Hygiene and Tropical Medicine Non-adherence is a big factor reducing the efficacy of tuberculo

CHARLES HICKS, Associate Professor Medicine, Duke University, Durham REFERENCE: Lancet 2006; 368: 466-75 Results with a new antiretroviral agent, tipranavir, tested among patients who were resistant t

Anthony Wierzbicki Gabriel Steg David Paquette Add HDL-Raising Therapy to Maximise Lipid Treatment REFERENCE: Abstract 53, Page 85 Anthony Wierzbicki, St Thomas’s Hospital, London The idea of ad

Carlo Pappone, San Raffaele University Hospital, Milan American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta The use of circumferential pulmonary vein ablation was found

Steven Nissen, Cleveland Clinic, Cleveland, Ohio American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta Among patients whose atheroma had been measured by a catheter ultra

Roy Gulick, Weill Cornell Medical College, New York Although the logic in antiretroviral HIV therapy has, for some years, been that two drugs are better than one; and three are better than two, this h

Freek Verheugt Shamir Mehta of McMaster University told Audio Medica in Stockholm about the OASIS-5/MICHELANGELO results comparing the new anti-thrombotic therapy, fondaparinux, with enoxaparin among